Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study
Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Prostate Cancer Management: Future Directions in Care
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Addressing Bone and Visceral Metastases in Metastatic CRPC
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Role of 177Lu-PSMA-617 in mCRPC and Bone Metastases
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
Selecting Among Novel Imaging Options in Metastatic CRPC
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Metastatic CRPC: Utility of Imaging as a Biomarker
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
DNA Alterations and Selection of PARP Inhibitors in mCRPC
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Overview of Therapy for mCRPC: PARP Inhibitors
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
Interpreting Data From the ARASENS Trial in Metastatic HSPC
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Selecting Optimal Therapy for mHSPC: Design of the ARASENS Trial
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
Role of Micronized Abiraterone in Metastatic HSPC
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.
Overview of Treatment for Metastatic HSPC
Expert perspectives on metastatic hormone-sensitive prostate cancer and the current state of the treatment armamentarium.
Monitoring Strategies in Nonmetastatic CRPC
A brief discussion on best practices in monitoring patients on therapy for nonmetastatic castration-resistant prostate cancer [nmCRPC].
Nonmetastatic Castration-Resistant Prostate Cancer: Quality of Life Measures
A brief review of the value of quality of life measures while managing patients on therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Factors in Selecting Novel AR-Targeted Therapy for Nonmetastatic CRPC
Comprehensive insight on selecting androgen receptor–targeted therapy for patients with nonmetastatic castration-resistant prostate cancer.
Evolving Treatment Landscape of Nonmetastatic CRPC
Focusing on nonmetastatic castration-resistant prostate cancer, panelists review the current treatment armamentarium and shared decisionmaking.
Optimizing Use of PSMA PET Imaging and PSADT in Prostate Cancer
Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Overview of Improvements in Prostate Cancer Management
Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512